Below is a list of helpful Web sites so that you can learn more about glaucoma and
your vision. These Web sites are neither owned nor controlled by Allergan. Allergan
is not responsible for the content or services on these sites.
-
Glaucoma Research Foundation
www.glaucoma.org
The Glaucoma Research Foundation works to prevent vision loss from glaucoma by investing
in innovative research, education, and support with the ultimate goal of finding
a cure.
-
National Eye Institute (NEI)
www.nei.nih.gov/health/glaucoma
As part of the federal government's National Institutes of Health (NIH), the National
Eye Institute’s mission is to "conduct and support research, training, health information
dissemination, and other programs with respect to eye diseases, visual disorders,
mechanisms of visual function, preservation of sight, and the special health problems
and requirements of the blind."
-
The Glaucoma Foundation (TGF)
www.glaucomafoundation.org
The Glaucoma Foundation's mission is to stimulate and support basic and applied
research in glaucoma, to gain and disseminate new information about the biological
causes and treatment of glaucoma, and to identify and develop novel approaches to
preserve visual function and reverse blindness caused by glaucoma.
-
American Glaucoma Society
www.glaucomaweb.org
The mission of the American Glaucoma Society is to promote excellence in the care
of patients with glaucoma and preserve or enhance vision by supporting glaucoma
specialists and scientists through the advancement of education and research.
-
Glaucoma Service Foundation to Prevent Blindness
www.willsglaucoma.org
The Glaucoma Service Foundation’s mission is to preserve or enhance the health of
all people with glaucoma and to provide a model of medical care by supporting the
educational and research efforts of the physicians on the Wills Eye Institute Glaucoma
Service, the largest glaucoma diagnosis and treatment center in the country.
LUMIGAN® 0.01% and 0.03% (bimatoprost ophthalmic solution) is used
for the treatment of high eye pressure, also called intraocular pressure (IOP),
in people with open-angle glaucoma or ocular hypertension.
Important Safety Information
LUMIGAN® 0.01% and 0.03% (bimatoprost ophthalmic solution) has been
reported to cause darkening (pigmentation) of eye color, eyelid skin, and eyelashes
as well as increased growth of eyelashes. Pigmentation changes can increase as long
as LUMIGAN® 0.01% and 0.03% is used. After stopping LUMIGAN®
0.01% and 0.03%, darkening of eye color is likely to be permanent, while darkening
of the eyelid skin and eyelash changes may be reversible. The effects of increased
darkening beyond 5 years are not known.
When only one eye is treated, there is a possibility of eyelash changes in the eye
treated with LUMIGAN® 0.01% and 0.03%. These changes may result in
differences between the eyes in eyelash length, thickness, darkness, number of eyelashes,
and/or direction of eyelash growth. These changes are usually reversible upon stopping
LUMIGAN® 0.01% and 0.03% therapy.
Avoid allowing the tip of the dispensing bottle to touch the eye, anything around
the eye, fingers, or any other surface in order to avoid contamination by common
bacteria known to cause eye infections. Serious damage to the eye and loss of vision
may result from using contaminated solutions.
If you have eye surgery or develop any eye reactions (such as trauma or infection),
immediately consult with your physician about continuing the use of LUMIGAN®
0.01% and 0.03%.
If you wear contact lenses, remove them before using LUMIGAN® 0.01%
and 0.03%. Then wait 15 minutes after using LUMIGAN® 0.01% and 0.03%
before you put your contacts back into your eyes.
The most common side effects are eye redness, growth of eyelashes, and itchy eyes.
Click here
for full prescribing information.